Compare ATEN & OCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ATEN | OCS |
|---|---|---|
| Founded | 2004 | 2003 |
| Country | United States | Switzerland |
| Employees | N/A | 3 |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.4B |
| IPO Year | 2014 | N/A |
| Metric | ATEN | OCS |
|---|---|---|
| Price | $23.88 | $26.42 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 6 |
| Target Price | $24.00 | ★ $42.00 |
| AVG Volume (30 Days) | ★ 800.9K | 332.0K |
| Earning Date | 04-30-2026 | 05-07-2026 |
| Dividend Yield | ★ 1.00% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.57 | N/A |
| Revenue | ★ $235,429,000.00 | N/A |
| Revenue This Year | $13.02 | $466.06 |
| Revenue Next Year | $10.39 | $479.73 |
| P/E Ratio | $42.07 | ★ N/A |
| Revenue Growth | ★ 2.36 | N/A |
| 52 Week Low | $13.81 | $14.00 |
| 52 Week High | $24.22 | $30.68 |
| Indicator | ATEN | OCS |
|---|---|---|
| Relative Strength Index (RSI) | 71.22 | 52.18 |
| Support Level | $17.12 | $25.99 |
| Resistance Level | N/A | $29.19 |
| Average True Range (ATR) | 0.71 | 1.22 |
| MACD | 0.14 | 0.16 |
| Stochastic Oscillator | 93.78 | 66.75 |
A10 Networks Inc is a provider of security and infrastructure solutions for on-premises, hybrid cloud, and edge-cloud environments of its multinational enterprise, communication, cloud and web service provider customers who strive to provide business-critical applications and networks that are secure, available, and efficient. As cyber-attacks increase in volume and complexity, the company integrates security and artificial intelligence (AI) enabled capabilities in its solutions that enable its customers to continue to adapt to market trends in hybrid cloud, AI-ready data centers and the ever-increasing need for high-performance, high availability and low latency. The company generates the maximum of its revenue from Americas.
Oculis Holding AG is a biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The Company has locations in five countries: Switzerland, Iceland, France, U.S. and Hong Kong.